Outpatient IV insulin
This article was originally published in The Gray Sheet
Executive Summary
CMS releases decision memo Dec. 23 ordering national non-coverage of outpatient intravenous insulin treatments, writing that the evidence does not support it as a reasonable and necessary service for diabetic Medicare patients. CMS opened a coverage analysis on the intermittent adjunct therapy last March (1"The Gray Sheet" March 30, 2009). Supporters claim the treatment can help prevent the onset of debilitating conditions and delay the need for more expensive therapies, such as dialysis (2"The Gray Sheet" May 4, 2009)
You may also be interested in...
IV Insulin Supporters Argue For Coverage On Basis Of Cost Effectiveness
Advocates of outpatient intravenous insulin treatment for diabetics argue it can help prevent the onset of debilitating conditions and delay the need for more expensive therapies, such as dialysis
CMS Exploring Coverage Of Outpatient Intravenous Insulin Treatments
Outpatient intravenous insulin treatment could gain traction as an adjunctive diabetes therapy under a CMS coverage analysis initiated March 25
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.